Pharmacological treatment of substance-abusing schizophrenic patients.
about
Q24197685Substance abuse and schizophrenia: pharmacotherapeutic interventionWorld Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia.World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Substance Use and Related Disorders, Part 1: Alcoholism.Psychotropic medication management in persons with co-occurring psychiatric and substance use disorders.BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP.Comorbidity and pattern of substance use in hospitalized psychiatric patients.Potential benefits of quetiapine in the treatment of substance dependence disordersNew pharmacological approaches for the treatment of alcoholism.The Potential Role of Long-acting Injectable Antipsychotics in People with Schizophrenia and Comorbid Substance Use.Treatment of substance use disorders in schizophrenia: a unifying neurobiological mechanism?Guidelines for biological treatment of substance use and related disorders, part 1: Alcoholism, first revision.Pharmacotherapy of Co-Occurring Schizophrenia and Substance Use DisordersClozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disorders.World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia. Part 3: Update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactatioPharmacological treatment of schizophrenia with comorbid substance use disorder.BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment.Substance abuse and lifestyle among an urban schizophrenic population: some observations.Prevalence of alcohol and drug abuse in schizophrenic inpatients.Quetiapine decreases alcohol consumption, craving, and psychiatric symptoms in dually diagnosed alcoholics.Aripiprazole reduces alcohol use.Differences in craving for cannabis between schizophrenia patients using risperidone, olanzapine or clozapine.Evidence-based guidelines for the pharmacological management of substance misuse, addiction and comorbidity: recommendations from the British Association for Psychopharmacology.Correlates of substance misuse in patients with first-episode schizophrenia and schizoaffective disorder.
P2860
Q24197685-CBD4BEC8-E4F3-4416-93E8-913A88FEF5B2Q24621711-25BF5063-127A-4CCF-94F8-48369BC64506Q33223628-39FDEBB1-505C-4902-BCED-D244F0B0C0E3Q33319816-09FC3A0C-D602-417B-8264-5E3C3FFA8082Q33637842-7C80E372-785A-451C-8F8D-BD724A0695DAQ34277168-130A3D4C-6069-4156-8569-39ECFB78A5FDQ34461463-07EF68BA-0317-4E07-95C5-627B4FC59AB3Q34554089-B31ECFD7-71EE-453B-A9B8-5EAA75D55F7EQ34582243-89BEA39A-A850-4F7F-ACB3-09CA7E7C8300Q36059843-379564C2-0059-422F-B8FF-08DA446141CFQ36228225-CB83856E-1290-4BB0-8161-D84A4E1F7686Q36231851-92EC8080-57B8-496D-BAE6-744A1CFBA5D0Q36927085-0116F192-ED91-4EA1-BEE8-FB30321EEE9BQ37075982-A6BBE596-187C-41A0-B477-A53D624F1A45Q38395937-50A12F39-7AA8-4597-9635-6D97BDD27582Q38658672-B6C2F805-209E-4ABC-9361-FB798B04D9E2Q38826206-4BE6A9A9-1459-4274-952C-97A71683770CQ39372312-EE2B3181-6245-4C9A-A334-D31CD17AD407Q40821996-3706FB06-1640-4024-9DC7-2C7105D8C703Q42163532-7BA1EC90-2B7E-43CF-97BD-A3A9964E697CQ46494443-1787277A-45BA-4CB9-AA59-A9F58A335E38Q49035384-5D69BC89-A88A-46C9-8435-432B5852ADB0Q51937580-8946B03D-61B3-486D-951A-FA1EFD0B4272Q52016145-50EEC7B8-F2F7-4D84-936B-CB8E29C992C8
P2860
Pharmacological treatment of substance-abusing schizophrenic patients.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 1990
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pharmacological treatment of substance-abusing schizophrenic patients.
@en
Pharmacological treatment of substance-abusing schizophrenic patients.
@nl
type
label
Pharmacological treatment of substance-abusing schizophrenic patients.
@en
Pharmacological treatment of substance-abusing schizophrenic patients.
@nl
prefLabel
Pharmacological treatment of substance-abusing schizophrenic patients.
@en
Pharmacological treatment of substance-abusing schizophrenic patients.
@nl
P921
P356
P1476
Pharmacological treatment of substance-abusing schizophrenic patients.
@en
P2093
P304
P356
10.1093/SCHBUL/16.1.111
P407
P577
1990-01-01T00:00:00Z